• Work Medical Technology Group entered strategic cooperation agreement with Shanghai Novabioplus Biotechnology on April 13, 2026 to jointly develop AI-driven medical models built on biological data.
• Partnership targets AI-led protein antibody therapeutics R&D by combining WORK Medical AI capabilities with Novabioplus protein datasets and reagent platforms.
• Collaboration also aims to create “BioTokens” tied to an intelligent digital protein database, seeking to turn biopharmaceutical R&D outputs into verifiable digital assets.
• Companies flagged potential joint investments in major projects as part of broader push to integrate industrial resources with capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Work Medical Technology Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110915PRIMZONEFULLFEED9717306) on May 11, 2026, and is solely responsible for the information contained therein.